Zvi Ram

Neurosurgeon, Head of Neurosurgery Department at Tel Aviv Sourasky Medical Center

Location:
Tel Aviv, Tel Aviv, Israel
Company:
Tel Aviv Sourasky Medical Center
Wrong Zvi Ram?

Last Updated 8/12/2017

General Information

Education

M.D.  - 

Affiliations

Professor and Head  - TAM

Medical Advisory Board Member  - Brain Tumor Biotech Center

Scientific Advisory Board Member  - ImmunoCellular Therapeutics, Ltd.

Member of the Executive Committee of the Section  - AANS/CNS

Web References  

Israeli doctors | MedPlus Ltd

Prof. Zvi Ram
Prof. Zvi Ram Neurosurgeon, head of Neurosurgery Department at The Tel Aviv Sourasky Medical Center . Graduated Sackler School of Medicine, today Dr. Ram is present professor of surgery (neurosurgery), that has an extensive practical experience recognized by several awards.

Read More
Israeli doctors | MedPlus Ltd

Prof. Zvi Ram
Prof. Zvi Ram Neurosurgeon, head of Neurosurgery Department at The Tel Aviv Sourasky Medical Center . Graduated Sackler School of Medicine, today Dr. Ram is present professor of surgery (neurosurgery), that has an extensive practical experience recognized by several awards.

Read More
Novocure Announces Six Clinical Presentations on Novocure's Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology | Business Wire

The six clinical presentations include an oral presentation by Zvi Ram, MD, Director of Neurosurgery at the Tel-Aviv Sourasky Medical Center in Tel-Aviv, focusing on how compliance and treatment duration may predict survival in newly diagnosed GBM patients treated with Optune® together with temozolomide.
Additionally, the presentations will highlight other learnings from the EF-14 trial dataset on the effects of Optune on health-related quality of life, time to functional and cognitive decline, analyses by Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) scores, patterns of Optune-related severe skin toxicity, and the use of Optune as a second-line treatment after first recurrence. "Novocure's EF-14 trial is the largest positive trial completed to date in newly diagnosed GBM and the trial dataset continues to provide new opportunities to deepen our understanding of Tumor Treating Fields in order to improve treatment outcomes for GBM patients," said Dr. Ram.

Read More

Browse ZoomInfo’s Directories